Table 3.
Proportion of patients on statin medication in each study group over time; n = 513
| Visit | CEA | CAS | BMT | total | p1 | p2 |
|---|---|---|---|---|---|---|
| Screening□ | 80.3% (163) | 73.6% (145) | 78.8% (89) | 77.4% (397) | 0.257⌐ | |
| D30 | 87.6% (163) | 86.7% (156) | 91.5% (97) | 88.1% (416) | 0.456⌐ | < 0.0001^* |
| M6 | 91.7% (166) | 86.9% (152) | 93.5% (101) | 90.3% (419) | 0.131⌐ | < 0.0001^* |
| A1 | 92.5% (160) | 87.6% (149) | 93.2% (96) | 90.8% (405) | 0.190⌐ | < 0.0001^* |
*Significant
⌐Chi2-test
^McNemar test
□Already published [23]; D30: Visit 30 days after screening visit; M6: Visit 6 months after screening visit; A1: Visit o ne year after screening visit
1testing CEA vs. CAS vs. BMT
2testing rate of statin medication on D30/M6/A1 vs. screening visit